EGFR and non-small cell lung carcinoma: According to a database24, the estimated frequencies of the three GOF mutations examined in our study—R248Q, R273H, and R175H—in patients with advanced NSCLC positive for activating mutations (L858R or exon-19 deletions) of EGFR are 0.80%, 0.91%, and 1.26%, respectively.